186 related articles for article (PubMed ID: 30953786)
1. Association of antieosinophil therapy with decreased body mass index in patients with severe asthma: A preliminary retrospective analysis.
Kuruvilla M; Patrawala M; Levy JM; Shih J; Lee FE
Ann Allergy Asthma Immunol; 2019 Jun; 122(6):649-650. PubMed ID: 30953786
[No Abstract] [Full Text] [Related]
2. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.
Strauss RA; Jawhari N
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):121-123. PubMed ID: 29684570
[No Abstract] [Full Text] [Related]
3. Update on immunogenicity in severe asthma: Experience with mepolizumab.
Ortega HG; Meyer E; Brusselle G; Asano K; Prazma CM; Albers FC; Mallett SA; Yancey SW; Gleich GJ
J Allergy Clin Immunol Pract; 2019; 7(7):2469-2475.e1. PubMed ID: 30954640
[No Abstract] [Full Text] [Related]
4. Eosinophils and interleukin-5: the debate continues.
Kay AB; Menzies-Gow A
Am J Respir Crit Care Med; 2003 Jun; 167(12):1586-7. PubMed ID: 12796050
[No Abstract] [Full Text] [Related]
5. Mepolizumab use: Post-approval academic practice experience.
Benjamin MR; Bochner BS; Peters AT
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):126-128. PubMed ID: 29653234
[No Abstract] [Full Text] [Related]
6. Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?
Castro M; Bacharier LB
Lancet; 2016 Oct; 388(10056):2059-2060. PubMed ID: 27609409
[No Abstract] [Full Text] [Related]
7. Eosinophils, beyond IL-5.
Esnault S; Johansson MW; Mathur SK
Cells; 2021 Oct; 10(10):. PubMed ID: 34685594
[TBL] [Abstract][Full Text] [Related]
8. Reslizumab (Cinqair) for severe eosinophilic asthma.
Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
[No Abstract] [Full Text] [Related]
9. Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response.
Drick N; Seeliger B; Welte T; Fuge J; Suhling H
BMC Pulm Med; 2018 Jul; 18(1):119. PubMed ID: 30021546
[TBL] [Abstract][Full Text] [Related]
10. Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab.
Bergantini L; d'Alessandro M; Cameli P; Bianchi F; Sestini P; Bargagli E; Refini RM
Int Arch Allergy Immunol; 2020; 181(10):746-753. PubMed ID: 32731216
[TBL] [Abstract][Full Text] [Related]
11. [Severe refractory eosinophilic asthma].
Jäger-Becker D
MMW Fortschr Med; 2016 Feb; 158(3):67. PubMed ID: 27119709
[No Abstract] [Full Text] [Related]
12. Benralizumab in Real Life.
Miralles López JC; Escudero Pastor AI; Carbonell Martínez A; Navarro Garrido C; Bonilla Pacheco Y; Petrik Petrik Y
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):87-88. PubMed ID: 32573458
[No Abstract] [Full Text] [Related]
13. Improved small airway dysfunction in severe asthma with clinical remission by anti-interleukin-5/interleukin-5 receptor α.
Akamatsu T; Shirai T; Okawa K; Hirai K
Ann Allergy Asthma Immunol; 2024 May; 132(5):648-650. PubMed ID: 38360105
[No Abstract] [Full Text] [Related]
14. Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma.
Ortega H; Yancey SW; Keene ON; Gunsoy NB; Albers FC; Howarth PH
J Allergy Clin Immunol Pract; 2018; 6(3):980-986.e1. PubMed ID: 29398640
[TBL] [Abstract][Full Text] [Related]
15. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
[TBL] [Abstract][Full Text] [Related]
16. Asthma Yardstick Update: Practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma.
Oppenheimer JJ; Borish L
Ann Allergy Asthma Immunol; 2018 Dec; 121(6):660-661. PubMed ID: 30172715
[No Abstract] [Full Text] [Related]
17. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.
Katz LE; Gleich GJ; Hartley BF; Yancey SW; Ortega HG
Ann Am Thorac Soc; 2014 May; 11(4):531-6. PubMed ID: 24606022
[TBL] [Abstract][Full Text] [Related]
18. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
19. Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab.
Han D; Lee JK
Ann Allergy Asthma Immunol; 2018 Dec; 121(6):742-743. PubMed ID: 30056148
[No Abstract] [Full Text] [Related]
20. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
Matera MG; Rogliani P; Calzetta L; Cazzola M
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):239-245. PubMed ID: 29268638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
